Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
- Conditions
- Interventions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00312728
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 50
- Registration Number
- NCT00309998
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00308529
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT00308516
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2009-08-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT00307723
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00307736
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 355
- Registration Number
- NCT00303628
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT00295503
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2010-06-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00294931
- Locations
- 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 21
- Registration Number
- NCT00287222
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Kansas University Medical Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.